{"id":"W2129229339","doi":"10.1212/wnl.0000000000001729","title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","year":2015,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":4543,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; National Eye Institute; Astellas Pharma; Novartis Pharma; Ministry of Education, Science and Technology; Multiple Sclerosis Society of Canada; European Committee for Treatment and Research in Multiple Sclerosis; Alexion Pharmaceuticals; National Institute of Neurological Disorders and Stroke; Teijin Pharma; Teva Pharmaceutical Industries; Acorda Therapeutics; Viropharma; GlaxoSmithKline; Biogen; Ono Pharmaceutical; Eisai; National Institutes of Health; Guthy-Jackson Charitable Foundation; Daiichi Sankyo Europe; Sanofi","keywords":"Neuromyelitis optica; Medicine; Multiple sclerosis; Neuroimaging; Consensus conference; Spinal cord; Serology; Pathology; Optic neuritis; Spectrum disorder; Aquaporin 4; Antibody; Immunology; Internal medicine; Psychiatry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}